H.C. Wainwright Reiterates Buy Rating on DiaMedica Therapeutics Inc. (DMAC)

April 1, 2026 6:57 AM

H.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $12.00 price target on DiaMedica Therapeutics Inc. (NASDAQ: DMAC).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found